Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV

Starting soon · Phase 2

Conditions studied: HPV, High-risk HPV (Any Strain), Human Papillomavirus (HPV) Infections

In brief

This is a randomized, open-label trial, to assess whether a single dose of HPV nonavalent vaccine, administered to HIV uninfected, unvaccinated women with high risk HPV16/18/31/33/45/52 or 58 can decrease the infectivity of shed HPV viruses. Our hypothesis is that vaccination will have little or no impact on HPV sample positivity by DNA PCR since the viral particles will continue to be produced and released, but that particles will be neutralized by vaccine-induced antibodies, thereby reducing their infective capacity. Cervical samples will be collected at randomisation and at 6 months, to compare infectivity of shed HPV viruses.

Key facts

Study ID

NCT07303751

Run by

Institut d'Investigació Biomèdica de Bellvitge

People needed

80

Starts

2026-02-01

Expected to finish

2027-02-01

Last updated by the study team

2026-02-11

Who can join

Age: 18 and older, up to 29. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Born female
• Aged between 18-29 years old;
• Living in Kambia district (or neighbouring district if included) without plans to move away in the next 12 months;
• Willing to participate in the study and have signed the informed consent form;
• In good health as determined by a medical history (a physical examination will be conducted if necessary according to the clinician's judgement);
• Willing to be tested for HIV;
• Are HIV negative at the screening visit;
• Not pregnant;
• Able to pass a Test of Understanding (TOU);
• Willing to provide cervical, urine and blood samples;
• Agree to be vaccinated with a single dose of Gardasil9® if randomised to the vaccine arm at Day 0;
• Have no visible suspicious cervical lesions on examination.
• Agree to a pregnancy test at screening and before any HPV vaccination.

You may not qualify if…

• They have been previously vaccinated against HPV;
• They have a chronic condition, such as autoimmune conditions, degenerative diseases, neurologic or genetic diseases among others;
• They are HIV positive or immunocompromised;
• They are pregnant or planning to get pregnant in the next 12 months;
• They are less than three months post-partum or currently breastfeeding;
• They are allergic to one of the vaccine components or to latex;
• They are sexually active and are not using, or are not willing to use, an effective birth control method from D-14 until 60 days after the last vaccine dose
• The nurse or clinician determining the eligibility, in agreement with principal investigator, considers that there is a reason that precludes participation.

Where it is running

• Kambia Research Centre — Freetown, Sierra Leone

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.